Quhill, F. and Beiderbeck, A. 2017. Cost Advantage of Fluocinolone Acetonide Implant (ILUVIEN®) versus Ranibizumab in the Treatment of Chronic Diabetic Macular Oedema. Global and Regional Health Technology Assessment. 4, 1 (Jul. 2017), 155–164. DOI:https://doi.org/10.33393/grhta.2017.391.